Palliative care for patients with irresectable or recurrent cancer of the upper gastrointestinal tract: a randomized study

ISRCTN ISRCTN86515732
DOI https://doi.org/10.1186/ISRCTN86515732
Secondary identifying numbers MEC-2005-176, NL628, NTR687
Submission date
19/07/2006
Registration date
19/07/2006
Last edited
08/01/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr P.D. Siersema
Scientific

Erasmus MC - University Medical Center Rotterdam
Department of Gastroenterology and Hepatology
Room HS 512
P.O. Box 2040
Rotterdam
3000 CA
Netherlands

Phone +31 (0)10 4632748
Email p.siersema@erasmusmc.nl

Study information

Study designRandomised controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeQuality of life
Scientific titlePalliative care for patients with irresectable or recurrent cancer of the upper gastrointestinal tract: a randomized study
Study acronymPACT study.
Study objectivesDoes nurse-led follow-up at home lead to improved quality of life and satisfaction and a reduction in costs compared to medical follow-up at the outpatient clinic, without compromising the medical condition of patients?
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedEsophageal, pancreatic or hepatobiliairy cancer
InterventionNurse-led follow-up at home at two-weekly and later monthly intervals until month 13 or death versus medical follow-up at the outpatient clinic at one month and thereafter every two months until month 13 or death
Intervention typeOther
Primary outcome measureQuality of life questionnaires
Secondary outcome measuresPatient satisfaction (questionnaire) costs
Overall study start date01/06/2006
Completion date01/01/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants150
Key inclusion criteria1. Patients with irresectabel or recurrent esophageal cancer, pancreatic cancer or hepatobiliary cancer, for whom no curative treatment options are available
2. Informed consent
Key exclusion criteria1. Not able to understand or read the Dutch language
2. Undergoing treatment with chemotherapy or radiotherapy or a combination
Date of first enrolment01/06/2006
Date of final enrolment01/01/2009

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Erasmus MC - University Medical Center Rotterdam
Rotterdam
3000 CA
Netherlands

Sponsor information

Health Care Research Program Erasmus MC 2003 (The Netherlands)
University/education

Erasmus MC - University Medical Center Rotterdam
Department of Gastroenterology and Hepatology
Room HS 512
P.O. Box 2040
Rotterdam
3000 CA
Netherlands

Funders

Funder type

University/education

Erasmus Medical Center
Government organisation / Universities (academic only)
Alternative name(s)
Erasmus Medical Center, Erasmus MC, Erasmus Universitair Medisch Centrum, Erasmus University Medical Center, Universitair Medisch Centrum Rotterdam, Erasmus Universitair Medisch Centrum Rotterdam, EMC
Location
Netherlands

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/03/2014 08/01/2021 Yes No

Editorial Notes

08/01/2021: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.
3. The NTR numbers have been added.